

## A Phase 1b Study with IMGN151 Monotherapy and Combinations in Subjects with Gynecologic Cancers

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- diagnosis of ovarian, fallopian tube, or primary peritoneal cancer - completed previous cancer treatment before starting the study and have recovered from treatment-related side effects - able to carry out normal daily activities with little or no assistance - see link to ClinicalTrials.gov for complete inclusion criteria

---

**Exclusion Criteria:**

- prior treatment with an FR $\alpha$ -targeted therapy - see link to ClinicalTrials.gov for complete exclusion criteria

### Conditions & Interventions

**Interventions:**

Drug: Bevacizumab, Drug: Carboplatin, Drug: IMGN151, Drug: Olaparib

**Conditions:**

Cancer

**Keywords:**

Clinics and Surgery Center (CSC), fallopian tube cancer, ovarian cancer, peritoneal cancer

### More Information

**Description:** This study is being done to test whether IMGN151, given alone or in combination with approved cancer treatments, is safe, well tolerated, and effective for treating ovarian, fallopian tube, or primary peritoneal cancer. Researchers will also study how the body responds to and processes IMGN151 when given at different doses.

**Study Contact:** Deanna Teoh - dkteoh@umn.edu

**Principal Investigator:** Deanna Teoh

**Phase:** PHASE2

**IRB Number:** STUDY00027148

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.